Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Total contract liabilities by Quarter
Total contract liabilities (deferred product & collaborative revenue, $M) ($M)
Vertex Pharmaceuticals Total contract liabilities: $157M in Q2 2026, up 6.9% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Revenue Disaggregation & Contract Balances Note.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total contract liabilities (deferred product & collaborative revenue, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 157 | +6.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 31, 2026 | 219 | -4.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 172 | -16.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q3 2025 | Sep 30, 2025 | 182 | -17.3% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 147 | +14.5% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 228 | -17.2% | Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 207 | +21.4% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 220 | +40.0% | Form 10-Q (filed 2024-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 128 | -28.4% | Form 10-Q (filed 2024-08-02) ↗ |
| Q1 2024 | Mar 31, 2024 | 276 | +16.7% | Form 10-Q (filed 2024-05-07) ↗ |
| Q4 2023 | Dec 31, 2023 | 170 | +6.7% | Form 10-K (filed 2025-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 157 | +31.5% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 179 | +32.9% | Form 10-Q (filed 2023-08-02) ↗ |
| Q1 2023 | Mar 31, 2023 | 236 | +27.0% | Form 10-Q (filed 2023-05-02) ↗ |
| Q4 2022 | Dec 31, 2022 | 160 | -7.0% | Form 10-K (filed 2024-02-15) ↗ |
| Q3 2022 | Sep 30, 2022 | 120 | +14.8% | Form 10-Q (filed 2022-10-28) ↗ |
| Q2 2022 | Jun 30, 2022 | 135 | +10.0% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2022 | Mar 31, 2022 | 186 | +2.7% | Form 10-Q (filed 2022-05-06) ↗ |
| Q4 2021 | Dec 31, 2021 | 172 | -10.3% | Form 10-K (filed 2023-02-10) ↗ |
| Q3 2021 | Sep 30, 2021 | 104 | +9.8% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2021 | Jun 30, 2021 | 123 | +73.4% | Form 10-Q (filed 2021-07-30) ↗ |
| Q1 2021 | Mar 31, 2021 | 181 | +137.5% | Form 10-Q (filed 2021-04-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 192 | +207.4% | Form 10-K (filed 2022-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 94.8 | +88.8% | Form 10-Q (filed 2020-10-30) ↗ |
| Q2 2020 | Jun 30, 2020 | 70.7 | +17.4% | Form 10-Q (filed 2020-07-31) ↗ |
| Q1 2020 | Mar 31, 2020 | 76.3 | +48.4% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2019 | Dec 31, 2019 | 62.3 | +150.2% | Form 10-K (filed 2021-02-11) ↗ |
| Q3 2019 | Sep 30, 2019 | 50.2 | +26.1% | Form 10-Q (filed 2019-10-31) ↗ |
| Q2 2019 | Jun 30, 2019 | 60.2 | +85.8% | Form 10-Q (filed 2019-08-01) ↗ |
| Q1 2019 | Mar 31, 2019 | 51.4 | +252.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 24.9 | +1,364.7% | Form 10-K (filed 2020-02-13) ↗ |
| Q3 2018 | Sep 30, 2018 | 39.8 | – | Form 10-Q (filed 2018-10-25) ↗ |
| Q2 2018 | Jun 30, 2018 | 32.4 | – | Form 10-Q (filed 2018-07-26) ↗ |
| Q1 2018 | Mar 31, 2018 | 14.6 | – | Form 10-Q (filed 2018-04-27) ↗ |
| Q4 2017 | Dec 31, 2017 | 1.70 | – | Form 10-K (filed 2019-02-13) ↗ |
Breakdown
What makes up total contract liabilities
Cite this data
StockData. (2026). Vertex Pharmaceuticals Total contract liabilities ($M), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/contract-liab-tot
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.